

HEALTHQUAL-Guyana Indicators for Round 1 Data Collection

I. Indicator for all

Eligibility: All patients with at least one visit during the 6 month review period

	Indicator	Rationale	Definition	Denominator	Numerator
1	Clinical Visits	Regular clinical visits are important to monitor growth, development and to identify patients who are eligible for vaccines. For patients with HIV, it's important to monitor progress, identify patients who are eligible for treatment and prophylaxis, to identify emerging problems as early as possible and identify patients lost to follow-up.	Proportion of patients having regular visits	Number of all eligible patients	Number of patients with at least 2 clinical visit in the past 6 months of the review period

II. Indicators for well child care < 5 years old (including those with HIV)

Eligibility: All children under five with at least one visit during the 6 month review period

	Indicator	Rationale	Definition	Denominator	Numerator
1	Growth Monitoring - Weight	Monitoring the growth of children less than five years of age is important in detecting those that might be under or over nourished or failing to thrive and in need of special management.	Proportion of children with weight measured at each clinic visit	Number of all eligible children	Number of children with weight measured at each clinic visit during the review period
2	Growth Monitoring – Height/Length		Proportion of children with height/length measured at each clinic visit	Number of all eligible children	Number of children with height/length measured at each clinic visit during the review period
3	Growth Monitoring – Head Circumference		Proportion of children with head circumference measured at each clinic visit	Number of all eligible children < 2 years of age	Number of children with head circumference measured at each clinic visit during the review period

4	Growth Monitoring – Weight for Age Plotted		Proportion of children with “Weight for Age” plotted among curves on Growth Chart	Number of all eligible children	Number of with “Weight for Age” plotted on Growth Chart at each clinic visit during the review period
5	Developmental Milestones Assessment	Children expected to achieve certain milestones in development by specific ages. The non-achievement of age specific developmental milestones may be early indications of children with special needs for whom early appropriate interventions could be instituted.	Proportion of children with developmental milestones assessed at each clinic visit	Number of all eligible children	Number of children with developmental milestones assessed at each clinic visit during the review period (as indicated on Clinic Card)
6	Vaccinations – Up to Date	Timely administration of age specific vaccines is important in preventing vaccine preventable diseases.	Proportion of children with all age-appropriate vaccines administered	Number of all eligible children	Number of children with all age-appropriate vaccines administered

III. Indicators for patients with HIV/AIDS

Eligibility: All exposed infants and patients with HIV, having at least one visit during the 6 month review period

	Indicator	Rationale	Definition	Denominator	Numerator
1	CD4 Monitoring	The degree of immune suppression can be established by determining a patient's CD4 cell count. The level then can be used to decide when to start ART and to monitor the effect of the treatment on the immune system. Where available, all HIV-infected patients should have their CD4 count measured every six months.	Proportion of patients who have had immune function assessed	Number of HIV+ patients	Number of patients with CD4 test during the 6 month review period
2	Antiretroviral Therapy	It is recommended that HAART is prescribed for all patients meeting Guyana's HAART eligibility criteria.	Proportion of patients prescribed HAART who meet eligibility criteria	Number of eligible patients who meet the HAART eligibility criteria *	Number of patients prescribed HAART
3	Adherence Assessment	High adherence is crucial to the success of ART at the individual and population levels. Routine assessment and support of adherence is critical to effective ART.	Proportion of patients prescribed ARVs who have had an adherence assessment at each clinic visit	Number of HIV+ patients prescribed HAART	Number of patients who have had an adherence assessment at each clinic visit during the 6 month review period
4a	Cotrimoxazole Prophylaxis - Infants	Cotrimoxazole prophylaxis has been shown to decrease mortality and the incidence of diarrhea, toxoplasmosis, pneumonia, <i>Pneumocystis</i> pneumonia, and sepsis in HIV exposed children and persons with advanced HIV disease. All HIV exposed children should get Cotrimoxazole from 4-6 weeks of age.	Proportion of patients receiving Cotrimoxazole who meet eligibility criteria	Number of exposed infants between 2 and 18 months of age	Number of exposed infants starting Cotrimoxazole by two months of age
4b	Cotrimoxazole Prophylaxis – HIV+			Number of HIV+ patient with CD4 <200 or with active TB	Number of patients receiving Cotrimoxazole during the six month review period
5	Tuberculosis – Screening	Tuberculosis is a common, and often deadly, opportunistic infection occurring disproportionately in patients with HIV. Screening patients for TB is an essential component of care that should be given to all eligible HIV-infected patients.	Proportion of patients who have been screened for TB with TST	Number of HIV+ patients never treated for TB, never having a + TST and not currently on treatment for TB	Number of patients who have been screened during the past 12 months with TST
6	General Medical Care	Changes in the body temperature, pulse or blood pressure can be early signs of underlying acute or chronic illnesses among clinic attendees. Monitoring of these parameters could facilitate early diagnosis of acute illnesses in children and chronic conditions in adults.	Proportion of patients with vital signs documented	Number of exposed infants and HIV+ patients	Number of patients with temperature and pulse documented at each clinic visit during the 6 month review period. For age 16+ add blood pressure.